Depression News and Research

Latest Depression News and Research

AstraZeneca/Targacept's TC-5214 for treatment resistant depression to earn Decision Resources' gold standard status

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for treatment resistant depression therapy, AstraZeneca/Targacept's TC-5214 will earn Decision Resources' proprietary clinical gold standard status in 2013 (following its approval that year) and through 2018.

20 Apr 2010

Homeopathy – Is it a safer and effective alternative?

Studies have shown that nearly 45% Britons rely on Homeopathy, a branch of medicine that has been doubted by many and loved by an equal number.

20 Apr 2010

Hospira enters definitive merger agreement to acquire Javelin Pharmaceuticals for $145M

Hospira, Inc., a global specialty pharmaceutical and medication delivery company, and Javelin Pharmaceuticals, Inc., today announced that the companies have entered into a definitive merger agreement providing for the acquisition of Javelin by Hospira for $2.20 per share in cash, or approximately $145 million. Hospira expects to commence a tender offer for all outstanding shares of Javelin common stock on or about April 21, 2010, in accordance with the terms of the merger agreement.

19 Apr 2010

Racial disparities in sleep and health-related quality of life

A study in the April 15 issue of the Journal of Clinical Sleep Medicine shows that having a sleep disturbance is associated with clinically meaningful reductions in health-related quality of life, and the magnitude of this effect varies by race and sleep disorder.

17 Apr 2010

Touch, massage can reduce stress/anxiety, pain, fatigue, depression and nausea in cancer patients

Sponsored by the National Cancer Institute, a recent research study has revealed that touch and massage, routinely administered by care partners significantly reduces the effects of cancer and the side-effects from its treatment while providing comfort and improvement in the quality of life. During the study, family caregivers learned touch and massage techniques from an instructional DVD.

17 Apr 2010

Researchers study effectiveness of TeleCare in keeping individuals healthy

Like the bleeps of an alarm clock, TeleCare, a home monitoring device, gives the chronically ill a wake-up call: "It's time to take your vitals."

17 Apr 2010

Repligen expects total revenue of $21.0M for fiscal year 2010

Repligen Corporation today announced preliminary financial results for fiscal year 2010 which ended March 31, 2010. Total revenue for the year is expected to be $21.0 million, including $10.3 million of bioprocessing product revenue and $10.7 million of royalty and other revenue. Research and development expenses are expected to be between $13.8-$14.2 million and selling, general and administrative expenses between $6.8-$7.2 million.

16 Apr 2010

RUCDR is poised to become a world leader in human disease and genome studies

Despite the continuing, crippling effects of a nationwide recession, a genetics research laboratory on Rutgers' Busch Campus is experiencing an economic boom.

16 Apr 2010

Sexual minorities more likely to experience posttraumatic stress disorder

A new study from researchers at the Harvard School of Public Health (HSPH) and Children's Hospital Boston has found that gay men, lesbians, bisexuals, and heterosexuals who have ever had a same-sex sex partner are one-and-a-half to two times as likely to experience violent events, especially in childhood, than the general population.

16 Apr 2010

New scale more suitable for predicting depressive symptoms

A research team has tested the utility of the short version of WHO-DAS II, a tool to assess within five minutes disability in patients with depression, "which in the case of primary care is even more practicable than the long version of the instrument." In Spain, more than 10% of the population suffer from severe depression.

16 Apr 2010

Study on primary cilia formation may lead to new therapies for ciliopathies

A team of scientists at the University of California, San Diego School of Medicine have identified a network of genes that initiate and manage cilia formation. Although scientists have known about cilia for decades, only recently have they discovered their role in disease. This new discovery, which may lead to new therapies for ciliopathies, will appear in the April 15 edition of Nature.

16 Apr 2010

New study describes impact of chronic pain on black men

Black men with chronic pain related to an accident, injury, illness, surgery or other causes were more likely to experience depression, affective distress and disability than white men with chronic pain, according to a new study by the University of Michigan Health System.

16 Apr 2010

Joint psychoanalytic treatment may benefit both mother and child

Even when a baby has been longed for, some mothers might have trouble bonding with their baby, who in turn may develop disturbed behaviour, such as crying, poor sleeping patterns and breast refusal.

15 Apr 2010

Rexahn Pharmaceuticals' Phase IIa clinical results of Serdaxin for MDD: Additional insights

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing potential best in class oncology and central nervous system (CNS) therapeutics, today offered additional commentary, clarifications and insights on yesterday's announcement of its Phase IIa clinical results of Serdaxin® in the treatment of major depressive disorder (MDD).

15 Apr 2010

Fathers of sexually abused children suffer from anxiety, grief and depression, says study

The preliminary results of a Universit- de Montr-al study show that fathers of sexually abused children can suffer from anxiety, depression and grief. Such patriarchs are often overwhelmed by a desire for vengeance, yet little literature exists to help them deal with their pain.

15 Apr 2010

Combivent Inhalation Aerosol's "essential use" status effective through 2013

Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced that the U.S. Food and Drug Administration (FDA) has determined that the "essential use" status of Combivent® (ipratropium bromide and albuterol sulfate) Inhalation Aerosol will be effective through December 31, 2013. With this ruling, COMBIVENT will remain on the market and available to the more than two million chronic obstructive pulmonary disease (COPD) patients who rely on it as a bronchodilator.

15 Apr 2010

Phase IIa clinical trial results of Serdaxin for treatment of MDD

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing potential best in class oncology and central nervous system therapeutics, today announced clinical results with its investigational new drug, Serdaxin®for the treatment of major depressive disorder.

15 Apr 2010

Parents' wartime deployment can have an impact on children’s behavioral problems

The current conflicts in Iraq and Afghanistan have resulted in extended and repeated combat-related deployments of U.S. military service members. While much has been reported about the problems, both physical and psychological, many bring back with them, new research out of UCLA shows that the family back home can have issues as well.

15 Apr 2010

Epilepsy patients who take Ginkgo products face increased risk of seizures: Report

Restrictions should be placed on the use of Ginkgo biloba - a top-selling herbal remedy - because of growing scientific evidence that Ginkgo may increase the risk of seizures in people with epilepsy and could reduce the effectiveness of anti-seizure drugs, a new report concludes. The article appears in ACS' monthly Journal of Natural Products.

15 Apr 2010

Family support critical for managing patients with chronic health problems

Almost 40 percent of chronically ill older adults in the U.S. live alone, and a majority of those who are married have spouses with at least one chronic illness that can affect their ability to provide support, according to a U-M study published in the journal Chronic Illness.

15 Apr 2010